Abstract: Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.

Abstract: Compounds of the formula (I) in which R1, R2, R3, R4 and R5 have the meanings indicated in claim 1 are inhibitors of tyrosine kinases, in particular of met kinase and can be employed inter alia for the treatment of tumors.

Abstract: Compounds of the formula (I), in which R1, R2, R3, R3?, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.

Abstract: The present invention relates to quinoxalinone derivatives of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein, as insulin secretion stimulators. Specific such quinoxaline compounds are also an aspect of the invention. The invention also relates to the preparation and use of these quinoxalinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.

Abstract: The invention relates to a method of aligning reactive mesogens (RM) on a substrate subjected to particle beam treatment, to RM's oriented by said method, especially in form of thin layers, to oriented polymers and polymer films obtained from such oriented RM's and RM layers, and to the use of the RM's, layers, polymers and films in optical, electronic and electrooptical applications.

Abstract: The invention relates to a liquid-crystalline medium having negative dielectric anisotropy which comprises at least one compound of the formula I in which R1, R1* and a have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the VA, PS-VA, PALC, FFS or IPS effect.

Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising a dielectrically neutral or slightly positive component, component A, comprising one or more dielectrically neutral or slightly positive compounds of the formula I in which the parameters have the meaning indicated in the specification, and a dielectrically positive component, component B, comprising one or more dielectrically positive compounds, and optionally a second dielectrically neutral component, component C, and to liquid-crystal displays containing these media, especially active-matrix displays and in particular TN, IPS and FFS displays.

Abstract: Novel imidazo[2,1-b][1,3,4]thiadiazole derivatives of formula (I) wherein R1 and R2 have the meaning according to claim 1, are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumors.

Abstract: The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments.

Abstract: The present invention relates to novel compounds of general formula (I) and uses thereof.

Abstract: The invention relates to a process for the preparation of bis(fluoroalkyl)phosphinyl chlorides or fluoroalkylphosphonyl dichlorides by reaction of the corresponding bis(fluoroalkyl)phosphinic acid or fluoroalkylphosphonic acid with aryltetrachlorophosphorane as chlorinating agent.

Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

Abstract: The invention relates to the compounds of the general formula (I): in which A, D, R, R1 and X are as defined in the description, to a process for the preparation thereof and to the therapeutic use thereof in the treatment of pathologies associated with insulin resistance syndrome.

Abstract: The present invention relates to a liquid-crystalline medium having high twist, to the use thereof for electro-optical purposes, and to displays containing this medium.

Abstract: The present invention relates to the use of phosphinic acids and/or phosphonic acids and salts thereof for wetting fluorine compounds, in particular fluoropolymers, to the use in coating solutions comprising fluorine compounds, and to polymerisation processes in which fluorine compounds are used and/or formed.

Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.

Abstract: The invention relates to the use of imidazole derivatives of the formula (1): in which A, R?1, R?2 and R?3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.

Abstract: The invention relates to a process for the preparation of a separating material having improved binding capacity, and to materials prepared and to the use thereof for the separation of charged or uncharged biopolymers from liquids.

Abstract: The present invention relates to a liquid-crystal (LC) display of the PS (polymer stabilized) or PSA (polymer sustained alignment) type, and to polymerizable compounds and LC media for use in PS (polymer stabilized) and PSA displays.

Abstract: The invention relates to an optically biaxial film comprising an anisotropic material with uniform helically twisted structure and a reflection wavelength below 400 nm, to methods and materials for its preparation, to its use as retardation or compensation film in optical devices like liquid crystal displays, and to compensators and liquid crystal displays comprising such a biaxial film.